AstraZeneca PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
AstraZeneca PLC Stock Forecast and Price Target
AstraZeneca PLC has an average price target of £162.02 recently offered by sixteen notable experts for 2024, which would represent a potential upside of approximately 34.72% from the last closing price in April, 2024 if reached. This potential increase is based on a high estimate of £220.19 and a low estimate of £125.02. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.
34.72% Upside
AstraZeneca PLC Fair Value Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Price has decreased In the last four years, from £69.51 to £0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will reach £140.05 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr866.80 | Buy/Sell | kr696.07 | 10.75% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.82 | Buy/Sell | $174.55 | 15.79% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.72 | Buy/Sell | $130.51 | 7.10% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.29 | Buy/Sell | $178.42 | 12.98% |
AstraZeneca PLC Revenue Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Revenue has grown in the last three years, jumping from £26.62B to £45.81B – an increase of 72.11%. In the next year, analysts predict that Revenue will reach £50.38B – an increase of 9.98%. For the next seven years, the forecast is for Revenue to grow by 41.93%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF90.00 | Buy/Sell | CHF105.00 | 19.58% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.86 | Buy/Sell | $118.92 | 18.38% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.38 | Buy/Sell | $303.65 | 17.77% |
.jpg)
AstraZeneca PLC Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's Dividend per Share has increased by 3.57%, going from £2.80 to £2.90. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach £3.16 – an increase of 8.97%. The AstraZeneca PLC forecast is for Dividend per Share to reach £5.28 or grow by 82.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.25 | Buy/Sell | $92.47 | 20.50% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.45 | Buy/Sell | $205.51 | -27.04% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.27 | Buy/Sell | $87.82 | 22.57% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.41 | Buy/Sell | £17.30 | 18.83% |
| MRK Stock Forecast | Merck KGaA | Outperform |
18
|
150.10€ | Buy/Sell | 190.06€ | 21.92% |
AstraZeneca PLC EBITDA Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's EBITDA has increased by 121.91% In the last three years, going from £6.76B to £15.01B. In the next year, analysts expect EBITDA to reach £18.11B – an increase of 20.62%. For the next seven years, the forecast is for EBITDA to grow by 49.72%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$230.48 | Buy/Sell | $284.47 | 21.49% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.77k | Buy/Sell | ¥5.24k | 21.70% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥4.86k | Buy/Sell | ¥4.92k | 26.54% |
AstraZeneca PLC EBIT Forecast for 2023 - 2025 - 2030
In the last three years, AstraZeneca PLC's EBIT has grown, increasing from £4.15B to £10.43B – a growth of 151.54%. The next year looks promising for AstraZeneca PLC, with analysts predicting EBIT of £17.26B – an increase of 65.42%. Over the next seven years, experts anticipate that AstraZeneca PLC's EBIT will grow at a rate of 152.82%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
10
|
$91.41 | Buy/Sell | $109.39 | 9.40% |
| BAS Stock Forecast | BASF | Outperform |
12
|
50.99€ | Buy/Sell | 49.50€ | 9.83% |
| LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF513.80 | Buy/Sell | CHF516.89 | 13.86% |
AstraZeneca PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's EPS has decreased In the last four years, from £4.02 to £0.00 – a 100.00% drop. In the next year, analysts predict that EPS will reach £8.10 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$106.18 | Buy/Sell | $135.42 | 17.16% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$54.70 | Buy/Sell | $61.72 | 17.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$202.46 | Buy/Sell | $299.62 | 42.50% |
.jpg)